Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy, Part II: Implementation

Area of Science:

• Oncology
• Surgical Oncology
• Gastroenterology

Background:

• Peritoneal carcinomatosis, originating from primary or metastatic cancers (e.g., ovarian, colorectal, appendiceal), presents a significant treatment challenge.
• Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as a complex but effective treatment modality.
• Improvements in morbidity, mortality, and quality of life have been observed in patients undergoing CRS with HIPEC.

Purpose of the Study:

• To explore the perioperative aspects of implementing CRS with HIPEC.
• To discuss patient care during CRS with HIPEC, emphasizing nursing considerations.
• To highlight the establishment of an interdisciplinary team and protocol development for this procedure.

Main Methods:

• Development of a written protocol by an interdisciplinary team at Holy Name Medical Center.
• Coordination of the surgical procedure within the operating room (OR).
• Focus on the perioperative care pathway for patients undergoing CRS with HIPEC.

Main Results:

• The implementation of CRS with HIPEC requires careful planning and coordination.
• A structured protocol is essential for the successful execution of the procedure.
• Perioperative nursing plays a critical role in managing patients undergoing CRS with HIPEC.

Conclusions:

• CRS with HIPEC is a viable and improving treatment option for peritoneal carcinomatosis.
• Effective implementation relies on multidisciplinary collaboration and standardized protocols.
• Specialized perioperative nursing care is paramount for optimizing patient outcomes.